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INTRODUCTION
Angiogenesis is essential for tumor growth and metasta-
sis. Tumors cannot exceed 1-2  L in volume without devel-
oping new blood vessels (1). These new vessels may allow
tumor dissemination by providing tumor cells with a portal
of entry into the circulation (2), and decreased angiogenesis
is associated with a decreased rate of metastasis (3).
Angiogenetic capacity, that is, the ability to induce neo-
vascularization, is characteristic of most neoplastic cells.
Among various angiogenic factors, vascular endothelial
growth factor (VEGF) is known as a powerful endothelial
cell-specific mitogen that is involved in tumor neovascular-
ization (4). VEGF is also a highly potent direct mediator of
microvascular permeability, and it is thought to be respon-
sible for the characteristic leakiness of tumor blood vessels
(5). VEGF expression has been demonstrated in a number
of human cancer cell lines (6), as well as in clinical speci-
mens of breast, brain, ovarian, esophageal, and colon cancer,
suggesting a trophic role of VEGF in supporting tumor
growth via host angiogenesis (7). In previous studies, VEGF
expression was significantly associated with the degree of vas-
cularization in non-small-cell lung cancer (NSCLC) (8, 9).
Although hypoxia is a strong inducer of VEGF (10), muta-
tionally activated ras or p53 oncogenes act synergistically
with hypoxia to induce VEGF expression (11, 12).
The wild-type (wt) p53 oncogene has recently been shown
to inhibit angiogenesis via regulation of thrombospondin-1,
an inhibitor of angiogenesis (13), and to down-regulate
VEGF-promoter activity (14). Mutant ras genes up-regulate
the expression of a variety of other growth factors thought to
have direct or indirect stimulating effects on angiogenesis,
e.g., transforming growth factor (TGF)- , TGF- , and
VEGF (15). Although experimental studies have shown that
mutant p53 and ras oncogenes contribute to angiogenesis
(11-15), there are few reports on the relationship between
these oncogenes and angiogenesis in NSCLC (16, 17).
Here, we investigated the relationship and correlation
between tumor angiogenesis and VEGF, mutant p53, and
K-ras protein expression by immunohistochemistry. In
addition, we evaluated the relationship between tumor
angiogenesis and overall survival.
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The Relationship between Microvessel Count and the Expression of
Vascular Endothelial Growth Factor, p53, and K-ras in Non-Small 
Cell Lung Cancer
Using immunohistochemical staining, we studied the relationship between the
microvessel count (MC) and the expression of K-ras, mutant p53 protein, and vas-
cular endothelial growth factor (VEGF) in 61 surgically resected non-small cell
lung cancers (NSCLC) (42 squamous cell carcinoma, 14 adenocarcinoma, 2 large
cell carcinoma, 2 adenosquamous carcinoma, and 1 mucoepidermoid carcino-
ma). MC of the tumors with lymph node (LN) metastasis was significantly higher
than that of tumors without LN metastasis (66.1±23.1 vs. 33.8±13.1, p<0.05).
VEGF was positive in 54 patients (88.5%). MC was 58.1±25.2 (mean±S.D.) in a
×200 field, and it was significantly higher in VEGF(+) tumors than in VEGF(-)
tumors (61.4±23.7 vs. 32.9±23.8, p<0.05). VEGF expression was higher in K-
ras-positive or mutant p53-positive tumors than in negative tumors (p<0.05). MC
was significantly higher in K-ras(+) tumors than in K-ras(-) tumors, although it did
not differ according to the level of mutant p53 protein expression. Survival did not
differ with VEGF, mutant p53, or K-ras expression, or the level of MC. In conclu-
sion, there is a flow of molecular alterations from K-ras and p53, to VEGF expres-
sion, leading to angiogenesis and ultimately lymph node metastasis. Correlations
between variables in close approximation and the lack of prognostic significance
of individual molecular alterations suggest that tumorigenesis and metastasis are
multifactorial processes.
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MATERIALS AND METHODS
Paraffin-embedded tumor specimens from 61 patients
with NSCLC who had undergone surgery at the Chonnam
National University Hospital were studied using immuno-
histochemistry. Pathologic and clinical data at the time of
surgery were reviewed to provide accurate staging. The
clinical follow-up of the patients (46 men and 15 women)
ranged from 1.5 to 75.7 months (average 18.5 months).
Tumors were staged and classified using the TNM staging
system (18) and the World Health Organization Histologi-
cal Classification (19) after a complete mediastinal lymph
node dissection in all cases. The mean age of patients was
56.3 yr (range, 31 to 71 yr). The characteristics of the pa-
tients are listed in Table 1. All the patients had an Eastern
Cooperative Oncology Group performance status of 0 or 1,
and normal findings on abdominal computed tomograms
and radionuclide bone scans. The histologic types included
42 squamous cell carcinoma, 14 adenocarcinoma, 2 large
cell carcinoma, 2 adenosquamous carcinoma, and 1 muco-
epidermoid carcinoma. TNM staging consisted of 1 Stage
Ia, 8 Ib, 13 IIb, 30 IIIa, and 9 IIIb. Patients who had died
within 1 month of the surgery were excluded.
Vascular endothelial growth factor (VEGF) expression
Immunohistochemical staining for VEGF was performed
using a Microprobe immuno/DNA staining system (Fisher
Scientific, Pittsburgh, PA, U.S.A.), which is based on capil-
lary action (20). Three-micrometer sections were cut from
paraffin blocks and mounted on Probe on Plus slides (Fisher
Scientific). Dewaxed sections were incubated with Pepsin
solution (Research Genetics, Huntsville, AL, U.S.A.) for 1
min at 45℃. After washing with Universal Buffer (Research
Genetics), sections from each tumor were incubated with
primary VEGF antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, U.S.A.) at a 1:50 dilution for 2 hr at room tem-
perature. The slides were washed with Universal Buffer and
incubated in biotinylated anti-mouse IgG (Sigma, St. Louis,
MO, U.S.A.) for 7 min at 45℃.
Endogenous peroxidase activity was blocked with Auto-
blocker (Research Genetics) for 5 min at 45℃. After wash-
ing with Universal Buffer, the sections were incubated with
streptavidin horseradish peroxidase (STR-HRP) (Research
Genetics) for 7 min at 45℃. The reaction products were
again washed in Universal Buffer, and then developed with
the chromogen 3-amino-9-ethylcarbazole (AEC) for 7 min
at 45℃. Sections were washed in running tap water and
lightly counterstained with hematoxylin. To evaluate
VEGF expression, a score corresponding to the percentage
of positive cells (0=0% positive cells, 1=≤10%, 2=10 to
25%, 3=26 to 50%, 4=≥50%) was established. Negative
controls were stained similarly, but without the primary
antibody. VEGF expression was considered positive if stain-
ing of the cytoplasm was seen in more than 25% of the
tumor cells in the slide containing the largest section of the
tumor.
Determination of microvessel count
Microvessels were identified by immunohistochemistry
using the CD34 mouse monoclonal antibody (QBEnd/10,
BioGenex, San Ramon, CA, U.S.A.) in a 1:50 dilution at
45℃ for 15 min.  The microvessel count (MC) was assessed
by light microscopy in the areas of the tumor containing
the highest number of capillaries and small venules at the
invasive edge, as described previously (21). The three highly
vascular areas were identified by scanning tumor sections at
low power×40 and×100). After the area of highest neo-
vascularization was identified on a×200 field×20 objec-
tive and (10 ocular, 0.739 mm2 per field), the highest value
was taken as the MC.
p53 and K-ras protein expression
Three-micrometer sections were cut from paraffin blocks
and mounted on Probe on Plus slides. Dewaxed sections,
were immersed in citric acid buffer (0.01 M, pH 6.0), and
then placed in a microwave oven at 100℃ for 10 min (for
p53). Sections from each tumor were incubated with prima-
ry antibodies for p53 (BP53.12, Zymed, South San Francis-
co, CA, U.S.A.) and K-ras (F234, Santa Cruz Biotechnolo-
gy, Santa Cruz, CA, U.S.A.) for 15 to 25 min. The slides
were washed with Universal Buffer and incubated with
biotinylated anti-mouse IgG for 7 min.
Endogenous peroxidase activity (for p53 and K-ras) was
blocked with Autoblocker for 5 min. After washing with
Universal Buffer, the sections were incubated with STR-
HRP (for p53 and K-ras) for 7 min. The reaction products
were again washed in Universal Buffer, then developed
Mean age (yr) 56.3±9.3
Male : Female 46 :15
Smoking (pack-years) 24.1±17.7 
Histology
Squamous cell carcinoma 42
Adenocarcinoma 14
Large cell carcinoma 2
Adenosquamous cell carcinoma 2
Mucoepidermoid carcinoma 1
N status
N0 15
N1-3 46
TNM stage  
≤ IIB 22
≥ IIIA 39
n=61
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using 3-amino-9-ethylcarbazole (AEC, for p53 and K-ras, 7
min) as a chromogen. All steps in the staining procedure
were done at 45℃. Sections were washed in running tap
water and lightly counterstained with hematoxylin. All pro-
cedures were performed using a Microprobe immuno/DNA
staining system, which is based on capillary action (23). Pos-
itive controls consisted of colon cancer for p53 and gastric
cancer for K-ras. For negative controls, the same positive
control slides were stained without the primary antibody.
The immunoreactivity of the slides was examined by two
investigators using standard light microscopy, and scored in
quartiles as the percentage of positive tumor cells: 0=0%,
1=≤10%, 2=10 to 50% and 3=≥50%. The intensity of
the staining reaction was not quantified.
K-ras immunoreactivity was defined as a diffuse cytoplas-
mic stain in neoplastic cells. p53 immunoreactivity was
defined as nuclear reactivity in neoplastic cells. The expres-
sion of p53 and K-ras was considered to be positive if
respective staining of the cytoplasm or nuclei was seen in
more than 10% of the tumor cells in the slide containing
the largest section of the tumor.
Statistical analyses
The statistical analyses were performed with the SPSS for
Windows program package. The survival time was recorded
in months (m) from the day of surgery. Univariate and mul-
tivariate analyses of survival data were undertaken, using
survival curves and applying the Kaplan and Meyer method
with log rank analysis, and the Cox regression model. Data
were expressed as the mean±standard deviation (S.D.). The
significance of associations was determined by using the 
2
test, Fisher’ s exact probability test, or a two-tailed Student’ s
t-test. p<0.05 was considered significant.
RESULTS
Microvessel count in tumors
Blood vessels were heterogeneously distributed in the
stroma of the tumors (Fig. 1A). The mean MC was 58.1±
25.2 and the median was 58 (range, 14-124) in a ×200
field. MC according to the pathologic state, and VEGF,
C D
A B
Fig. 1. A: Tumor area with high microvessel count in squamous cell carcinoma (ABC method, ×200). B: cytoplasmic VEGF expression
in squamous cell carcinoma (×200). C: p53 protein accumulation in the nuclei of neoplastic cells in squamous cell carcinoma (×200).
D: Cytoplasmic K-ras  expression in squamous cell carcinoma (×200).420 Y.-H. Kang, K.-S. Kim, Y.-K. Yu, et al.
mutant p53, and K-ras protein expression are shown in
Table 2. There was no significant difference in MC among
the different histological subtypes of NSCLC. In addition,
MC was not significantly different between low stage (≤
Stage IIb) and advanced stage (≥ Stage IIIa). The patients
with lymph node metastasis had a higher MC than those
without metastasis (66.1±23.1 vs. 33.8±13.1, p<0.001).
VEGF expression and microvessel count
VEGF expression was mainly identified in the cytoplasm
of tumor cells (Fig. 1B). Positive staining for VEGF was seen
in 54 out of 61 cases (88.5%). MC of VEGF-positive tumors
was significantly higher than that of VEGF-negative tumors
(61.4±23.7 vs. 32.9±23.8, p=0.004) (Table 2). VEGF
expression did not differ according to lymph node metastasis
or stage (low stage vs. advanced stage) (Table 3).
p53 staining, microvessel count, and VEGF
Mutant p53 was stained in the nuclei of neoplastic cells
(Fig. 1C). Of 61 specimens, 34 (55.7%) stained positive for
mutant p53 protein. p53 expression did not differ according
to lymph node metastasis or stage. MC did not differ between
p53-positive and p53-negative tumors (61.7±30.8 vs. 55.3
±19.7, p=0.353) (Table 2).  However, VEGF expression in
p53-positive tumors (33/34, 97.1%) was greater than that in
p53-negative tumors (21/27, 77.8%) (p=0.037) (Table 3).
K-ras staining, microvessel count, and VEGF
K-ras was stained in the cytoplasm of neoplastic cells
(Fig. 1D). Forty-seven specimens stained positive for K-ras
protein (77%). K-ras expression did not differ according to
lymph node metastasis or stage (data not shown). MC in K-
ras-positive tumors was significantly higher than that in K-
ras-negative tumors (62.0±25.6 vs. 45.2±19.6, p= 0.028)
(Table 2). VEGF expression in K-ras-positive tumors (45/
47, 95.7%) was greater than that in K-ras-negative tumors
(9/14, 64.3%) (p=0.005) (Table 3).
Overall survival analysis
The three-year survival rate (YSR) was higher in low
stages (≤IIb) than in advanced stages (≥IIIa) (3YSR:
79.8% vs. 28.8%, p=0.0043) (Fig. 2). The patients were
divided into two groups: those with low MC (<58) or high
MC (≥58: median of MC). The overall survival did not dif-
fer between the low and high MC groups (Fig. 3A). In
addition, the overall survival did not differ according to
VEGF, p53, or K-ras expression (Fig. 3B, 4). The univariate
analysis using a Cox regression model (shown in Table 4)
underlines the strong prognostic relevance of TNM stage
(p=0.0098).
Total 58.1±25.2
Histologic types
Squamous cell carcinoma (n=42) 57.5±24.2
Non-squamous cell carcinoma (n=19) 59.6±27.9 0.766
Lymph nodal status
N1-N3 (n=46) 66.1±23.1
N0 (n=15) 33.8±13.1 0.000
TNM stage
≤ IIB (n=22) 50.6±28.9
≥ IIIA (n=39) 62.4±22.2 0.081
VEGF expression
Positive (n=54) 61.4±23.7
Negative (n=7) 32.9±23.8 0.004
P53 expression
Positive (n=34) 55.3±19.7
Negative (n=27) 61.7±30.8 0.353
K-ras expression
Positive (n=47) 62.0±25.6
Negative (n=14) 45.2±19.6 0.028
Factors Microvessel counts p value
Table 2. Correlation between the microvessel counts and
VEGF expression, mutant p53 protein, K-ras protein expres-
sion in tumor tissue
Age (yr) 0.987 0.450-2.167 0.97
Sex 2.267 0.775-6.636 0.14
Lymph node status 2.617 0.781-8.769 0.12
TNM stage 4.938 1.471-16.581 0.0098
Microvessel counts 1.124 0.512-2.469 0.77
VEGF 1.083 0.324-3.626 0.90
Mutant p53 2.233 0.930-5.365 0.07
K-ras 0.924 0.385-2.218 0.86
Factors Hazard ratio 95% Confidence interval p value
Table 4. Results of Cox regression analysis in 61 patients with
NSCLC; univariate analysis of the various prognostic factors
Lymph node status
Negative 4 11
Positive 3 43 0.055
TNM stage
≤ IIB 4 18
≥ IIIA 3 36 0.240
Mutant p53
Negative 6 21
Positive 1 33 0.037
K-ras
Negative 5 9
Positive 2 45 0.005
VEGF expression
Factors p-value
Negative (n=7) Positive (n=54)
Table 3. VEGF expression according to the expression of
mutant p53, K-ras protein, lymph nodal status, and TNM stage
Age; 0: <58, 1: ≥58, Sex: 0: Female, 1: Male. Lymph node status; 0:
Negative, 1: Positive. TNM stage; 0: ≤IIB, 1: ≥IIIA. Microvessel count;
0: less than median, 1: equal or greater than median. Other factors; 0:
negative, 1: positive.Factors Affecting Angiogenesis in Non-Small Cell Lung Cancer 421
DISCUSSION
Various growth factors stimulate angiogenesis, including
acidic fibroblast growth factor (aFGF), basic fibroblastic
growth factor (bFGF), TGF- , TGF- , platelet-derived
endothelial cell growth factor, hepatocyte growth factor,
and VEGF (1, 7). In this study we focused on the role of
VEGF.
As a result of alternative splicing of messenger RNA,
VEGF exists as four different homodimeric molecular
species; the monomers have 121, 165, 189, or 206 amino
acids (VEGF121, VEGF165, VEGF189, VEGF206,
respectively) (4). VEGF121 and VEGF165 are soluble pro-
teins, whereas VEGF189 and VEGF206 are bound to hep-
arin-containing proteoglycans on the cell surface or in the
basement membrane (22). Experiments utilizing the gene
transfection method (23, 24) have established strong evi-
dence for a contribution of VEGF to the progressive growth
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of solid tumors through its effects in promoting tumor
angiogenesis.
Numerous cytokines and growth factors produced by
tumor and normal cells affect VEGF expression. It has been
reported that VEGF expression is enhanced by epidermal
growth factor, keratinocyte growth factor, TGF- , TGF- ,
insulin-like growth factor I, PGE2, IL-1 , IL-1 and IL-6
(7). In addition, oncogenes, such as p53 and ras, affect VEGF
expression. VEGF overexpression was correlated with nucle-
ar accumulation of p53 in human lung and colon cancer (12,
16). Likewise, vessel counts in p53-positive tumors were sig-
nificantly higher than in p53-negative tumors (15). Besides
mutant p53, mutation of the ras gene also has been shown to
up-regulate VEGF expression (11, 15).
As in other reports (8, 16, 25, 26), our results showed
that lymph node (LN) metastasis was associated with the
microvessel count. In addition, our data are in agreement
with previous studies, in that VEGF expression was signifi-
cantly associated with the degree of vascularization in
NSCLC (8, 9). However, there were no direct correlations
between LN metastasis and VEGF expression. These find-
ings suggest that there are many other factors controlling
the degree of LN metastasis that cannot be explained by
VEGF expression alone.
In this study, p53 and K-ras were shown to have no direct
effect on lymph node metastasis. However, both oncopro-
teins were correlated with VEGF expression. VEGF expres-
sion is correlated with the onset of mutations in both ras
(11) and p53 (12), and these mutations act synergistically
with hypoxia to induce VEGF expression. Our data also
showed that K-ras expression was correlated with MC,
while p53 expression was not. These results suggest that K-
ras induces angiogenesis via VEGF expression.
If we postulate a sequential pathway of angiogenesis,
oncogenes (p53 and K-ras), VEGF expression, microvessel
count (angiogenesis), and finally degree of metastasis can be
lined up. We observed a direct relationship between the
closely approximated variables; however, direct relation-
ships between distant variables are hard to prove. These
findings suggest that there are many other factors control-
ling the dependent variable, since it cannot be explained
with only one or two independent variables.
Although the role of VEGF in tumor metastasis has been
demonstrated by several experiments that showed that VEGF
induces neovascularization (1), the association of VEGF
expression with the prognosis of NSCLC is controversial.
Imoto et al. reported poor survival in VEGF-immunopositive
NSCLC (27). However, Decaussin et al. (28) argued against
this finding by demonstrating that positive staining for
VEGF did not indicate a poor prognosis. Our data showed
that survival did not differ according to VEGF expression.
Some studies have found that patients with p53-positive
tumors have a significantly poorer prognosis in lung cancers
(29), whereas others have found no differences in survival
between p53-positive and p53-negative lung cancers (30).
Moreover, a recent study by Lee et al. (31) showed that p53
expression implied a favorable prognosis in a series of 156
resected primary NSCLC. According to our data, p53 expres-
sion did not affect patient survival.
VEGF expression can be induced by the mutant ras onco-
gene (15), and mutant K-ras knockout sublines were incapable
of forming tumors in nude mice (11). Furthermore, in serum-
starved NIH 3T3 cells, a ras-transformed cell line expresses
enhanced levels of VEGF transcripts (32). Although the K-ras
mutation is known to be a poor prognostic factor in pul-
monary adenocarcinoma (33), our data did not show any
survival difference according to K-ras expression.
The prognostic significance of angiogenesis in NSCLC
has not been established. Giatromanolaki et al. (25) and
Harpole et al. (34) reported that vascularity was a signifi-
cant factor in predicting poor survival. However, this study
and others (10, 35) have found no differences in survival
according to MC in lung cancer.
In conclusion, there is a flow of molecular alterations
from K-ras and p53, and VEGF expression, that lead to
angiogenesis and finally to lymph node metastasis. Correla-
tions between variables in close approximation and the lack
of prognostic significance of individual molecular alter-
ations suggest that tumorigenesis and metastasis are multi-
factorial processes.
As shown in the report by Kim et al. (36), however, anti-
VEGF monoclonal antibody inhibits the growth of rhab-
domyosarcoma (A673) and leiomyosarcoma (SK-LMS-1)
cell lines, and the magnitude of the response is greater in
rhabdomyosarcoma, which proliferates more rapidly and is
therefore more angiogenesis-dependent. The important role
of VEGF expression in angiogenesis in NSCLC suggests a
potential therapeutic use of anti-VEGF monoclonal anti-
body for blocking VEGF action in this type of tumor.
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